Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$0.38 USD
+0.01 (2.80%)
Updated Apr 18, 2024 03:46 PM ET
After-Market: $0.37 -0.01 (-2.30%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 101 - 120 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
2Q Review: Aramchol Is a Contender for NASH; Affirm Buy, PT to $36 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Takeaways from Our Expert Call on ARREST Phase 2b Results
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Connecting the Dots of ARREST: Dial in to our Expert Call on July 24, 12PM (ET)
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Connecting the Dots of ARREST: Dial in to our Expert Call on July 24, 12PM (ET)
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
The Sleeper NASH Readout of 2018 Has Awoken; Heading to Phase 3; Raise PT to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - NASH Weekly: Our Clinicaltrials.gov tracker - Who Entered the NASH Arena?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
1Q18: ARREST on Track for June; Additional Doors Opened for Combos
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Large Pharma Are Not the Only Ones to Fill the Rooms at EASL
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
A Closer Look into Aramchol''s Antifibrotic Effect at EASL
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y